Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05003453

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator

Sponsor: RDC Clinical Pty Ltd

Conditions Eczema, Atopic

Interventions 1.5% Palmitoylethanolamide (PEA) sold as Levagen+ Placebo Comparator

Updated 6 times since 2021 Last updated: Nov 15, 2023 Started: Nov 29, 2021 Primary completion: Jun 3, 2022 Completion: Jun 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05003453, this PHASE2/PHASE3 trial focuses on Eczema, Atopic and remains completed. Sponsored by RDC Clinical Pty Ltd, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Sep 2022 — Dec 2023 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RDC Clinical Pty Ltd

Data source: RDC Clinical Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, Australia